News

Belgium’s Ogeda to be bought by Astellas

Monday 3 April 2017
Country
Belgium

The privately-owned Belgian drug developer Ogeda SA is to be acquired by Astellas Pharma Inc of Japan in a deal potentially valued at €800 million. Ogeda is developing products for women’s health that target G-protein coupled receptors (GPCRs).

Sirukumab trial results in The Lancet

Sunday 2 April 2017
Country
United States

A Phase 3 trial in which patients with active rheumatoid arthritis (RA) were treated with the monoclonal antibody sirukumab, or placebo, met its primary endpoint of relief from swelling even in those who had failed to respond to two or more biological drugs.

Meeting Report: Opportunities in cell and gene therapy

Saturday 1 April 2017
Country
Spain

The opportunities for commercialising cell and gene therapies appeared relatively bright as the first quarter drew to a close, helped by new finance and the prospective approval of the first cancer products made from engineered T cells.

Pancreatic cancer trial suspended

Saturday 1 April 2017
Country
United States

An early clinical trial of a candidate treatment for pancreatic cancer developed by Halozyme Therapeutics Inc has been suspended after the independent data monitoring committee determined that it was unlikely to improve the patients’ overall survival.

Daratumumab study in non-Hodgkin’s lymphoma stopped

Friday 31 March 2017
Country
Denmark

A Phase 2 study of the monoclonal antibody daratumumab in three types of non-Hodgkin’s lymphoma has been stopped early because it failed to reach predefined targets for overall response, Genmab A/S announced on 30 March.

Novartis CAR T therapy to get priority review

Thursday 30 March 2017
Country
Switzerland

Novartis has become the second developer to have a candidate chimeric antigen receptor T (CAR T) cell therapy for cancer accepted by the US Food and Drug Administration for review. If successful, the two applications will mark a new era in cancer therapy.

Pivotal year for RNAi?

Thursday 30 March 2017
Country
United Kingdom

Could 2017 be a pivotal year for RNAi? According to Ali Mortazavi, the chief executive of Silence Therapeutics Plc, this is a strong possibility if upcoming data from the trial of a short interfering RNA (siRNA) molecule being developed by Alnylam Pharmaceuticals Inc are positive.

Mereo BioPharma in share placement for orphan drug

Wednesday 29 March 2017
Country
United Kingdom

Mereo BioPharma Group Plc has announced a private share placement intended to raise £15 million to support development of a treatment for osteogenesis imperfecta, a genetic disorder characterised by bones that break easily.

BerGenBio issues shares on Oslo Stock Exchange

Wednesday 29 March 2017
Country
Norway

The Norwegian oncology developer BerGenBio ASA is making an initial public offering of its shares on the Oslo Stock Exchange in order to support development of a Phase 2 compound targeting three cancer indications.

Ocrevus approved in US for MS

Wednesday 29 March 2017
Country
United States

A monoclonal antibody developed by Genentech (Roche) for multiple sclerosis (MS) has been approved for marketing in the US, the first therapy to show a delay in disability for those with progressive forms of the disease. In clinical trials, Ocrevus performed better than Rebif, the standard of care.